Pacira BioSciences, Inc. (PCRX) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong revenue growth, improved net income, and expanding market presence, especially with EXPAREL. The company projects double-digit growth and margin improvements, while new product launches and market expansion strategies are positive indicators. Despite the lack of detailed risk discussion and unclear Q&A responses, the overall financial performance and strategic outlook suggest a positive sentiment. The absence of significant negative factors, combined with optimistic guidance, supports a positive stock price movement prediction.
Key Financial Performance
Revenue Pacira BioSciences reported revenue of $200 million for Q1 2026, representing a 10% increase year-over-year. The growth was driven by strong demand for their flagship product, EXPAREL, and increased adoption in outpatient settings.
Net Income The company achieved a net income of $25 million, up 15% compared to the same period last year. This improvement was attributed to higher revenues and effective cost management strategies.
Gross Margin Gross margin for the quarter was 75%, a 2% improvement year-over-year. The increase was due to operational efficiencies and a favorable product mix.
Operating Expenses Operating expenses were $100 million, a 5% increase from Q1 2025. The rise was primarily due to investments in R&D and marketing initiatives.
Cash Flow Cash flow from operations was $50 million, a 20% increase year-over-year, driven by improved profitability and efficient working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects to achieve double-digit revenue growth over the next three years, driven by increased adoption of its flagship product, EXPAREL, and expansion into new markets.
Product Launches: Pacira plans to launch two new products in the next 18 months, which are expected to contribute significantly to revenue growth.
Market Expansion: The company is focusing on expanding its presence in international markets, particularly in Europe and Asia, to drive future growth.
Revenue Expectations: Pacira projects revenue to grow by 15% to 20% annually over the next three years.
Margin Projections: The company anticipates improving its operating margins by 200 basis points annually through cost optimization and operational efficiencies.
Capital Expenditures: Planned capital expenditures are expected to increase by 10% next year to support infrastructure expansion and product development.
Market Trends: The company expects a recovery in elective surgeries, which will positively impact demand for its products.
Business Segment Performance: The EXPAREL segment is expected to continue its strong performance, contributing significantly to overall revenue growth.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Anthea Li
BioSciences Inc
Brendan Teehan
Director Brendan
Division Anthea
Division Hardik
Division Jeevan
Division PM
Division Serge
Douglas Tsao
EDT day
Frank Lee
HC Wainwright
Hardik Parikh
Head Investor
Inc Conference
Investor Relations
Jeevan Larson
Jefferies LLC
Jonathan Slonin
LLC Research
Larson Truist
Li Jefferies
Officer Douglas
Officer Jonathan
Officer Shawn
PM EDT
Relations Frank
Relations statement
Research Division
Serge Belanger
PCRX Transcript
Pacira BioSciences, Inc. (PCRX) Q1 2026 Earnings Call Transcript
Positive4-30
The earnings call summary indicates strong revenue growth, improved net income, and expanding market presence, especially with EXPAREL. The company projects double-digit growth and margin improvements, while new product launches and market expansion strategies are positive indicators. Despite the lack of detailed risk discussion and unclear Q&A responses, the overall financial performance and strategic outlook suggest a positive sentiment. The absence of significant negative factors, combined with optimistic guidance, supports a positive stock price movement prediction.
Pacira BioSciences, Inc. (PCRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
Pacira BioSciences, Inc. (PCRX) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call shows strong financial performance with revenue and margin improvements, alongside optimistic future guidance. Key growth drivers include EXPAREL's market expansion and improved reimbursement. The Q&A reveals management's confidence in growth strategies, despite some vague responses. The stock buyback plan and raised guidance further enhance positive sentiment. Overall, these factors suggest a positive stock price movement, although the lack of specific market cap information limits the prediction's precision.
Pacira BioSciences, Inc. (PCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
PCRX Slides
PCRX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
